UCSF Home Page About UCSF Search UCSF Website UCSF Medical Center Home Page UCSF Cancer Center Website


Scientific Publications

(not including clinical studies)

 

Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DA, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Res Treat. 2016; 155:431-40. PMID 26860947. PMCID: PMC4767608.

 

Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10:e0121607. PMID: 25901353. PMCID: PMC4406848.

 

Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 1:1154-61. PMID: 26204261.

 

Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015; 6: 41123-33. PMID 26516700. PMCID: PMC4747394.

 

Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015; 14: 1-13. PMID 26438156. PMCID: PMC4674361.

 

Campbell MR and Moasser MM. HER targeting in HER2-negative Breast Cancers: Looking for the HER3 positive. Clin Cancer Res 2015; 21:2886-8. PMID 25609069. PMCID: PMC4490014.

 

Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene 2015; 34:5288-94. PMID 25619841. PMCID: PMC4515412.

 

Moasser MM. Two Dimensions in Targeting HER2. J Clin Oncol 2014; 32: 2074-7. PMID: 2486026. PMCID: PMC4517047.

 

Littlefield P, Moasser MM, Jura N. An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Chem Biol. 2014; 21:453-8. PMID: 24656791. PMCID: PMC4018233.

 

Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73:1168-79. PMID: 23243018. PMCID: PMC3563920.

 

Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signaling is regulated through a multitude of redundant mechanisms in HER2-driven tumor cells. Biochemical J  2012; 447:417-25. PMID:22853430.

 

Spassov DS, Wong CH, Harris G,McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM.  A tumor suppressing function in the epithelial adhesion protein Trask. Oncogene 2012; 31:419-31. PMID: 21706059. PMCID: PMC3184310

 

Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle 2011; 10: 1225-32. PMID: 21490433.

 

Spassov DS, Wong CH, Ahuja D, Moasser MM. The structural features of Trask that mediate its anti-adhesive function. PLoS One 2011; 6: e19154. PMID: 21559459. PMCID: PMC3084758.

 

Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011; 31:766-82. PMID: 21189288; PMCID: PMC3028653.

 

Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010; 21: 944-50. PMID: 20816829; PMCID: PMC2991618.

 

Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010; 16:1373-83. PMID: 20179223; PMCID: PMC2831167.

 

Amin DA, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science TM 2010; 2(16): p16ra7. PMID: 20371474; PMCID: PMC3033659.

 

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen L, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid tumor malignanices. Clin Cancer Res 2009; 15: 5569-75. PMID: 19706807; PMCID: PMC3029022.

 

Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation.  Am J Pathol 2009 174: 1756-1765. PMID: 19349359; PMCID: PMC2671264.

 

Arkin M & Moasser MM. HER2 directed small molecule antagonists. Curr Opin Investigat Drugs 2008; 9: 1264-76. PMID: 19037833; PMCID: PMC3031872.

 

Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009; 15: 2311-2322. PMID: 19318475; PMCID: PMC3023342.

 

Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009; 29:1071-9. PMID: 19388114.

 

Torbett NE, Luna A, Knight ZA, Houk A, Moasser MM, Weiss W, Shokat KA and David Stokoe. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. Biochemical J 2008; 415: 97-110. PMID: 18498248; PMCID: PMC3079392.

 

Chien AJ & Moasser MM. Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. Semin Oncol 35(Suppl 2); S1-S14 (2008). PMID: 18410794.

Wieduwilt WJ & Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell & Mol Life Sci 2008; 65: 1566-84. PMID: 18259690; PMCID: PMC3060045.

 

Sergina NV & Moasser MM. The HER family: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13; p527-534 (2007). PMID: 17981505; PMCID: PMC3035105.

Hsieh AC & Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97; p453-457 (2007). PMID: 17667926;  PMCID: PMC2360352.

 

Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26; p6577-6592 (2007). PMID: 17486079; PMCID: PMC3071580.

 

Moasser MM. The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26; p6469-6487 (2007). PMID: 17471238; PMCID: PMC3021475.

 

Moasser MM, Wilmes LJ, Wong CH, Li K, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Mag Res Imag 2007 26:1618-25. PMID: 17968965; PMCID: PMC3024590.

 

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3. Nature 445; p437-441 (2007). PMID: 17206155; PMCID: PMC3025857.

 

Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion Signaling by a novel mitotic substrate of src kinases. Oncogene 24; p5333-5343 (2005).

Mizenina OA & Moasser MM. S-phase Inhibition of Cell Cycle Progression by a Novel Class of Pyridopyrimidine Tyrosine Kinase Inhibitors. Cell Cycle 3; p796-803 (2004).

 

She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib (ZD1839, Iressa) in PTEN null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling. Clinical Cancer Research 2003; 9: 4340-4346.

 

Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of  Bcr-abl driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research 2003;  9: 1267-1273.

 

Moasser MM & Rosen N. Molecular markers in the farnesyltransferase inhibitor (FTI) therapy of breast cancers. Breast Cancer Research & Treatment 2002; 73:135-144.

 

Munster PN. Srethapakdi M. Moasser MM. Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells Cancer Research 2001; 61:2945-52.

 

Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumors. Cancer Research 2001; 61: 7184-7188.

 

Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Farnesyl:protein transferase inhibitors as potential agents for the management of prostate cancer. Prostate Cancer and Prostatic Diseases 2001; 4: 33-43.

 

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, and Rosen N. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Research 1999; 54: 6145-6152.

 

Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Baalog A, Su D, Danishefsky SJ, and Rosen N. Farnesyl Transferase Inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl. Acad. Sci. USA 1999; 95: 1369-1374.